S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Better Than Oil Stocks (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
In a good sign for China's struggling economy, factory activity grows for the first time in 6 months
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
MarketBeat Week in Review – 9/25 - 9/29
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
6.5 Million Americans Are DESPERATE for This New Drug from One Tiny Company (Ad)
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
OTCMKTS:CAPS

Capstone Therapeutics (CAPS) Stock Forecast, Price & News

$7.50
0.00 (0.00%)
(As of 09/29/2023 ET)
Compare
Today's Range
$7.50
$7.50
50-Day Range
$7.50
$7.50
52-Week Range
$5.00
$20.00
Volume
N/A
Average Volume
5 shs
Market Capitalization
$600,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

CAPS stock logo

About Capstone Therapeutics (OTCMKTS:CAPS) Stock

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.

CAPS Price History

CAPS Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Capstone Holding Corp. Announces CFO Change
Guess What The Fed Is Doing To Your Money Now?
For years, the Federal Reserve has been printing mountains of money jacking up interest rates and driving the U.S. into a recession. And just a few weeks ago, they did something even more disturbing. And hardly anyone is talking about it. Yet this could harm you more than money printing and interest rates. It made a frightening power grab of the U.S. dollar, and it could cause you to lose control of your cash.
Capstone Therapeutics Corp
Hormel Foods announces free downtown concert
Max Q: Grounded
Stocks Build on Gains
See More Headlines
Receive CAPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Capstone Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CAPS Company Calendar

Last Earnings
8/13/2018
Today
9/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CAPS
Employees
2
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
45,000
Market Cap
$600,000.00
Optionable
Not Optionable
Beta
131.81
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael M. Toporek (Age 57)
    CEO, Pres & Chairman
  • Edward Schultz
    VP,CFO & Treasurer
  • Mr. Matthew E. Lipman (Age 44)
    VP, Sec. & Director













CAPS Stock - Frequently Asked Questions

How have CAPS shares performed in 2023?

Capstone Therapeutics' stock was trading at $37.00 on January 1st, 2023. Since then, CAPS shares have decreased by 79.7% and is now trading at $7.50.
View the best growth stocks for 2023 here
.

How were Capstone Therapeutics' earnings last quarter?

Capstone Therapeutics Corp. (OTCMKTS:CAPS) announced its quarterly earnings data on Monday, August, 13th. The biotechnology company reported $0.02 EPS for the quarter. The biotechnology company earned $2 million during the quarter.

What other stocks do shareholders of Capstone Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capstone Therapeutics investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Akero Therapeutics (AKRO), CymaBay Therapeutics (CBAY), Cumberland Pharmaceuticals (CPIX), Entasis Therapeutics (ETTX), Evelo Biosciences (EVLO), Kaleido Biosciences (KLDO).

What is Capstone Therapeutics' stock symbol?

Capstone Therapeutics trades on the OTCMKTS under the ticker symbol "CAPS."

How do I buy shares of Capstone Therapeutics?

Shares of CAPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capstone Therapeutics' stock price today?

One share of CAPS stock can currently be purchased for approximately $7.50.

How much money does Capstone Therapeutics make?

Capstone Therapeutics (OTCMKTS:CAPS) has a market capitalization of $600,000.00.

How can I contact Capstone Therapeutics?

Capstone Therapeutics' mailing address is 1275 W. Washington Street Suite 104, Tempe AZ, 85281. The official website for the company is www.capstonethx.com. The biotechnology company can be reached via phone at (708) 371-0660, via email at investorinquiries@capstonethx.com, or via fax at 602-286-5300.

This page (OTCMKTS:CAPS) was last updated on 9/30/2023 by MarketBeat.com Staff

My Account -